Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gentronix Unveils New Corporate Identity and Website

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Gentronix offers GreenScreen® HC and BlueScreen™ HC assays.

Gentronix has revealed a new corporate identity and re-designed website. The new identity has been developed to reflect how the company has evolved into a mainstream provider of early screening in vitro genetic toxicology assays, and mechanistic follow-up, to a range of business sectors including pharmaceuticals, chemicals, agrochemicals, flavours fragrances and taste enhancers, and the personal care and consumer product industries.

In addition to classical in vitro early screening assays, such as the Ames bacterial mutation reversal and Micronucleus tests, Gentronix offers their proprietary GreenScreen® HC and BlueScreen™ HC assays.

The company also supports clients in the development of de-risking strategies and carrying out further assays to determine the mechanism and causes of positive genotox screening results.

As such, Gentronix has a wealth of knowledge and experience in the field and this is reflected in the new website at www.gentronix.co.uk which hosts content on the science of genotoxicity, regulations for each industry sector, screening procedures, as well as links to an extensive range of peer reviewed papers.

John Nicholson, CEO at Gentronix, comments, “In recent years we have greatly diversified our range of genotoxicity screening product and service offerings. We also provide advice on dealing with positive results and are able to offer a variety of further assays and strategies to help understand the mechanism of genotoxicity. This updating of our corporate identity has been undertaken to better reflect this. These are exciting times for Gentronix, and we feel that the new identity and website helps us to build on our strong foundations to move the business forward.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.
Thursday, December 20, 2012
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Scientific News
Breast Cancer Cells Found To Switch Molecular Characteristics
Spontaneous interconversion between HER2-positive and HER2-negative states could contribute to progression, treatment resistance in breast cancer.
Some Breast Cancer Patients With Low Genetic Risk Could Skip Chemotherapy
Genetic test can help predict survival and guide treatment options.
Lose Weight, Escape the Eight: Weight-Based Cancer Risk
IARC has identified eight additional cancer sites linked to overweight and obesity.
Coffee Consumption Linked to Genes
Researchers have identified a gene that influences coffee consumption. The gene is thought to relate to caffeine breakdown.
Emerging Model of Cancer
Cancer acts cooperatively, making individual decisions but acting in unison; this insight is being used to create a computer model of cancer.
Biological Barcodes Using CRISPR
Using genome editing tools, researchers are getting closer to understand differentiation of various cell types during development.
Controlling DNA Repair
Scientists discover that DNA repair outcomes following CRISPR-Cas9 cleaving are non-random and can be harnessed to produce desired effects.
Demonstrating LNP Delivery of CRISPR Components
Intellia has presented data demonstrating in vivo gene editing ising liquid nanoparticles (LNPs) to deliver CRISPR/Cas9.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Creating Embryos with 'Heteroplasmy'
New discovery in genetic research could lead to treatments for mitochondrial diseases.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!